• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 5. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948

• Solvents and Organic Chemicals Organic Compounds Organosulfur compounds Thioureas Thioureas
• Solvents and Organic Chemicals Organic Compounds Organosulfur compounds Thioureas

Recent Advances in the Study of 1,3-bis(hydroxymethyl)thiourea (CAS: 3084-25-1): Applications and Mechanisms in Chemical Biology and Medicine

1,3-bis(hydroxymethyl)thiourea (CAS: 3084-25-1) is a thiourea derivative that has garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications. Recent studies have explored its role as a crosslinking agent, antimicrobial compound, and potential therapeutic agent. This research brief synthesizes the latest findings on this compound, focusing on its molecular mechanisms, synthetic applications, and biological activities.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 1,3-bis(hydroxymethyl)thiourea exhibits potent antimicrobial properties against drug-resistant bacterial strains. The research team employed molecular docking simulations to elucidate its binding affinity with bacterial enzymes, revealing a unique mechanism of action that disrupts cell wall synthesis. These findings suggest its potential as a lead compound for developing novel antibiotics.

In materials science, researchers have utilized 1,3-bis(hydroxymethyl)thiourea as a key component in polymer synthesis. A recent ACS Applied Materials & Interfaces publication (2024) highlighted its effectiveness as a crosslinker for producing hydrogels with enhanced mechanical properties and biocompatibility. The study reported a 40% improvement in tensile strength compared to conventional crosslinkers, making it particularly valuable for biomedical applications such as wound dressings and drug delivery systems.

Pharmacokinetic studies conducted in 2024 have provided new insights into the compound's metabolic pathways. Using LC-MS/MS techniques, researchers identified three primary metabolites and characterized their biological activities. Interestingly, one metabolite showed enhanced anti-inflammatory effects compared to the parent compound, opening new avenues for drug development. These findings were published in Drug Metabolism and Disposition.

The compound's safety profile has been systematically evaluated in recent preclinical trials. A comprehensive toxicology study (2023) using rodent models established an LD50 of 1,250 mg/kg, with no observed genotoxic effects at therapeutic doses. However, researchers noted dose-dependent hepatotoxicity at concentrations above 500 mg/kg, emphasizing the need for careful dosage optimization in therapeutic applications.

Emerging research suggests potential anticancer applications of 1,3-bis(hydroxymethyl)thiourea derivatives. A 2024 Nature Communications paper reported that structurally modified analogs demonstrated selective cytotoxicity against triple-negative breast cancer cells while sparing normal cells. The proposed mechanism involves inhibition of thioredoxin reductase, a key enzyme in cancer cell redox homeostasis.

Future research directions include optimizing the compound's physicochemical properties for enhanced bioavailability and exploring its combination with other therapeutic agents. Several pharmaceutical companies have included 1,3-bis(hydroxymethyl)thiourea derivatives in their preclinical pipelines, indicating growing industry interest in this versatile chemical entity.

• 1768-59-8((E)-N-phenyl-N'-(phenylamino)carbamimidothioic acid)
• 2293-07-4((4-methoxyphenyl)thiourea)
• 56-04-2(Methylthiouracil)
• 56-10-0(S-(2-Aminoethyl)-ITU dihydrobromide)
• 102-08-9(1,3-diphenylthiourea)
• 141-90-2(2-Thiouracil)
• 591-28-6(4-Thiouracil)
• 645-48-7((phenylamino)thiourea)
• 1516-37-6((2-Methoxyphenyl)thiourea)
• 3696-22-8(1-(4-Nitrophenyl)-2-thiourea)